TScan Therapeutics Inc (TCRX) USD0.0001
Sell:$3.07Buy:$3.11
No change
Prices delayed by at least 15 minutes
- This stock can be held in a
Stocks and Shares ISASell:$3.07
Buy:$3.11
Change:No change
No changePrices delayed by at least 15 minutes
Sell:$3.07
Buy:$3.11
Change:No change
No changePrices delayed by at least 15 minutes
Director deals
Listed below are trades carried out by directors and other individuals which are required to be notified to the market.
Recent deals
| Date | Name and position (if held) | Deal type | Number of shares dealt | Price per share | Value of trade | Shares remaining |
|---|---|---|---|---|---|---|
| 13 December 2024 | LYNX1 CAPITAL MANAGEMENT LPInvestment Management Company | Buy Regular purchase transaction | 100,000 | $2.90 | $290,140.00 | 5,357,347 |
| 12 December 2024 | LYNX1 CAPITAL MANAGEMENT LPInvestment Management Company | Buy Regular purchase transaction | 31,800 | $3.01 | $95,628.96 | 5,257,347 |
| 15 November 2024 | LYNX1 CAPITAL MANAGEMENT LPInvestment Management Company | Buy Regular purchase transaction | 947 | $4.34 | $4,113.96 | 5,225,547 |
| 23 September 2024 | Barbara KlenckeIndependent Director | Buy Regular purchase transaction | 5,000 | $5.29 | $26,450.00 | 45,000 |
| 26 August 2024 | Barbara KlenckeIndependent Director | Buy Regular purchase transaction | 5,000 | $5.53 | $27,650.00 | 40,000 |
| 23 August 2024 | Barbara KlenckeIndependent Director | Buy Regular purchase transaction | 5,000 | $5.69 | $28,450.00 | 35,000 |
| 23 August 2024 | Zoran ZdraveskiChief Legal/Compliance Officer | Sell Regular sell transaction (market) | 164,686 | $5.78 | $952,115.64 | 4,716 |
| 19 April 2024 | BAKER BROS ADVISORS LPHedge Fund | Buy Regular purchase transaction | 8,851,451 | $7.13 | $63,109,960.48 | 43,158,741 |
| 19 April 2024 | LYNX1 CAPITAL MANAGEMENT LPInvestment Management Company | Buy Regular purchase transaction | 5,000,000 | $7.13 | $35,649,500.00 | 5,000,000 |
| 19 April 2024 | BAKER BROS ADVISORS LPHedge Fund | Buy Regular purchase transaction | 825,968 | $7.13 | $5,889,069.24 | 4,018,678 |
5 most significant deals
| Date | Name and position (if held) | Deal type | Number of shares dealt | Price per share | Value of trade | Shares remaining |
|---|---|---|---|---|---|---|
| 19 April 2024 | BAKER BROS ADVISORS LPHedge Fund | Buy Regular purchase transaction | 8,851,451 | $7.13 | $63,109,960.48 | 43,158,741 |
| 19 April 2024 | LYNX1 CAPITAL MANAGEMENT LPInvestment Management Company | Buy Regular purchase transaction | 5,000,000 | $7.13 | $35,649,500.00 | 5,000,000 |
| 19 April 2024 | BAKER BROS ADVISORS LPHedge Fund | Buy Regular purchase transaction | 825,968 | $7.13 | $5,889,069.24 | 4,018,678 |
| 23 August 2024 | Zoran ZdraveskiChief Legal/Compliance Officer | Sell Regular sell transaction (market) | 164,686 | $5.78 | $952,115.64 | 4,716 |
| 13 December 2024 | LYNX1 CAPITAL MANAGEMENT LPInvestment Management Company | Buy Regular purchase transaction | 100,000 | $2.90 | $290,140.00 | 5,357,347 |
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Director deal information provided by Factset.